RecruitingPhase 2Phase 3NCT07079735
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)
Sponsor
Columbia University
Enrollment
150 participants
Start Date
Sep 12, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria1
- Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.
Exclusion Criteria1
- History of or suspected CMV disease within 6 months prior is excluded.
Interventions
DRUGLetermovir
CMV prophylaxis
DRUGValganciclovir
Standard therapy for CMV prophylaxis
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07079735